Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Advances in host-directed therapies against tuberculosis / / Petros C. Karakousis, Richard Hafner, Maria Laura Gennaro, editors
| Advances in host-directed therapies against tuberculosis / / Petros C. Karakousis, Richard Hafner, Maria Laura Gennaro, editors |
| Edizione | [1st ed. 2021.] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (XIII, 332 p. 20 illus.) |
| Disciplina | 616.079 |
| Soggetto topico | Immunotherapy |
| ISBN | 3-030-56905-5 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Section 1: Introduction -- Chapter 1: Introduction: An overview of host-directed therapies for tuberculosis -- Section 2: Targeting immunometabolism -- Chapter 2: Sirtuin deacetylases: Linking Mycobacterial infection and host metabolism -- Chapter 3:The mammalian target of rapamycin complex 1 (mTORC1): an ally of M. tuberculosis in host cells -- Chapter 4: HIF-1α as a potential therapeutic target for tuberculosis treatment -- Chapter 5: Nuclear receptors in host-directed therapies against tuberculosis -- Section 3: Enhancing anti-mycobacterial mechanisms -- Chapter 6: Autophagy as a target for host-directed therapy against tuberculosis -- Chapter 7: Metformin: a leading HDT candidate for TB -- Chapter 8: Statins as host-directed therapy for tuberculosis -- Chapter 9: Antimycobacterial attributes of mitochondria: An insight into host defense mechanisms -- Section 4: Targeting immune cells -- Chapter 10: Conventional and unconventional lymphocytes in immunity against Mycobacterium tuberculosis -- Chapter 11: Targeting inhibitory cells such as Tregs and MDSCs in the tuberculous granuloma -- Chapter 12: Targeting suppressor T cells -- Chapter 13: Neutrophil-mediated mechanisms as targets for host-directed therapies against tuberculosis -- Chapter 14: Type I interferon and interleukin-1 driven inflammatory pathways as targets for HDT in tuberculosis -- Chapter 15: Mucosal-associated invariant and Vγ9Vδ2 T cells -- Chapter 16: Airway epithelial cells.-Section 5: Preclinical models for assessing HDTs -- Chapter 17: In vitro models of human granuloma formation to analyze host-directed therapies -- Chapter 18: C3HeB/FeJ as a key mouse strain for testing host-directed therapies against tuberculosis -- Chapter 19: The Rabbit Model for Assessing Host-Directed Therapies for Tuberculosis -- Section 6: Clinical trials of HDTs and special considerations for study endpoints -- Chapter 20:Clinical trials of TB-HDT candidates -- Chapter 21:Outcomes for clinical trials of host-directed therapies for tuberculosis -- Chapter 22: Pharmacological considerations for clinical trials of host-directed therapies for tuberculosis. |
| Record Nr. | UNINA-9910484717803321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advances in Immunology and Immuno-techniques : Updated Concepts and Recent Applications / / edited by Alok Das Mohapatra, Priyadarshi S. Sahu
| Advances in Immunology and Immuno-techniques : Updated Concepts and Recent Applications / / edited by Alok Das Mohapatra, Priyadarshi S. Sahu |
| Autore | Das Mohapatra Alok |
| Edizione | [1st ed. 2024.] |
| Pubbl/distr/stampa | Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2024 |
| Descrizione fisica | 1 online resource (309 pages) |
| Disciplina | 616.079 |
| Altri autori (Persone) | SahuPriyadarshi S |
| Collana | Interdisciplinary Biotechnological Advances |
| Soggetto topico |
Immunology
Biotechnology Biology - Technique Immunotherapy Biological Techniques Applied Immunology |
| ISBN |
9789819755080
9789819755073 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1. Immunologic Basis of Immuno-therapeutics and Vaccines: Present Approaches and Future Perspectives -- Chapter 2. Blocking Co-inhibitory Receptors: A Promising Cancer Immunotherapy Strategy -- Chapter 3. Neoepitope-based Cancer Vaccines: Principle and Applications -- Chapter 4. Bispecific Antibodies: An Emerging Concept in Antibody-based Cancer Therapies -- Chapter 5. Progresses and Challenges in HIV Vaccine -- Chapter 6. Neurobiological Mechanisms of Maternal Immune Activation-induced Neurodevelopmental Disorders: A Serotonin Model -- Chapter 7. Immunopharmacogenomics: Challenges and Future Prospects -- Chapter 8. Immunology Encounters Nano-technology: Recent Developments and Future Prospects of Nano-based Drug Delivery Systems -- Chapter 9. Novel Drug Targets in Neuro-immune Disorders -- Chapter 10. The Role of Host Genetics in the Susceptibility, Severity, and Immune Response to SARS-CoV-2 -- Chapter 11. Immuno Metabolic Interplay in Health and Disease -- Chapter 12. Role of Human Milk Immune Modulators on Infant’s Health. |
| Record Nr. | UNINA-9910908366503321 |
Das Mohapatra Alok
|
||
| Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advances in molecular pathology / / edited by Felipe Simon and Carmelo Bernabeu
| Advances in molecular pathology / / edited by Felipe Simon and Carmelo Bernabeu |
| Edizione | [First edition 2023.] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2023] |
| Descrizione fisica | 1 online resource (336 pages) : illustrations |
| Disciplina | 410 |
| Collana | Advances in Experimental Medicine and Biology |
| Soggetto topico |
Pathology, Molecular
Leukemia Melanoma Immunotherapy |
| ISBN |
9783031261633
9783031261626 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | SECTION 1: Molecular pathology of immune, inflammatory, and hemostatic disorders -- Immune responses at host barriers and their importance in systemic autoimmune diseases -- Statins and hemostasis: therapeutic potential based on clinical evidence -- Effects of adrenergic receptor stimulation on human hemostasis: A systematic review -- α1-adrenergic stimulation increases platelet adhesion to endothelial cells mediated by TRPC6 -- Physical Activity, Burnout, and Engagement in Latin American Students of Higher Education during the COVID-19 Pandemic -- Small plastics, big inflammatory problems -- Impact of a community-based pelvic floor kinesic rehabilitation program on the quality of life of Chilean adult women with urinary incontinence -- SECTION 2: Molecular pathology of endocrine and muscular disorders -- Iodine intake based on a survey from a cohort of women at their third trimester of pregnancy from the Bosque County Chile -- Appraisal of the neuroprotective effect of dexmedetomidine: a meta-analysis -- Bile acids alter the autophagy and mitogenesis in skeletal muscle cells -- Upregulation of CCL5/RANTES gene expression in the diaphragm of mice with cholestatic liver disease -- Differential fibrotic response of muscle fibroblasts, myoblasts, and myotubes to cholic and deoxycholic acids -- BMAL1 regulates glucokinase expression through E-box elements in vitro -- SECTION 3: Molecular pathology of cancer: determinants and potential therapies -- Correlation between endoglin and malignant phenotype in human melanoma cells: analysis of hsa-mir-214 and hsa-mir-370 in cells and their extracellular vesicles -- Increase in Frequency of Myeloid-Derived Suppressor Cells in the Bone Marrow of Myeloproliferative Neoplasm: Potential Implications in Myelofibrosis -- The “Ins and Outs” of prostate specific membrane antigen (PSMA) as specific target in prostate cancer therapy -- Transforming Growth Factor-β1 in Cancer Immunology: opportunities for immunotherapy. |
| Record Nr. | UNINA-9910717422603321 |
| Cham, Switzerland : , : Springer, , [2023] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antifungals : from genomics to resistance and the development of novel agents / / edited by Alix T. Coste, Institute of Microbiology, University Hospital Lausanne, and University Hospital Center, Lausanne, Switzerland, and Patrick Vandeputte, Host-Pathogen Interactions Study Group, UPRES-EA 3142, L'UNAM Angers University, and Parasitology-Mycology Laboratory, University Hospital Center, Angers, France
| Antifungals : from genomics to resistance and the development of novel agents / / edited by Alix T. Coste, Institute of Microbiology, University Hospital Lausanne, and University Hospital Center, Lausanne, Switzerland, and Patrick Vandeputte, Host-Pathogen Interactions Study Group, UPRES-EA 3142, L'UNAM Angers University, and Parasitology-Mycology Laboratory, University Hospital Center, Angers, France |
| Pubbl/distr/stampa | Norfolk, England : , : Caister Academic Press, , [2015] |
| Descrizione fisica | 1 online resource (346 p.) |
| Disciplina | 616.969061 |
| Soggetto topico |
Immunotherapy
Antifungal agents Biofilms |
| Soggetto genere / forma | Electronic books. |
| ISBN | 1-910190-02-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Contents; Contributors; Preface; 1: Molecular Mechanisms of Resistance of Candida spp. to Membrane-targeting Antifungals; Introduction; Azoles; Non-azole ergosterol biosynthesis inhibitors; Polyenes; Concluding remarks; 2: Point Mutations and Membrane-targeting Antifungal Resistance in Aspergillus fumigatus and Other Non-Candida Species; Introduction; Aspergillus fumigatus azole resistance in clinical settings; The molecular target of azoles, allylamines and polyenes: ergosterol and ergosterol biosynthesis pathway; Differences in ergosterol pathway between Aspergillus spp. and yeasts
Fungal 14-a sterol demethylases (SDMs): the main target for azole antifungalsA. fumigatus azole susceptibility patterns and mechanisms of azole resistance linked with CYP51 point mutations; Azole resistance in non-fumigatus Aspergillus; Azole secondary resistance linked with point mutations in the 14-α sterol demethylase enzyme in non-Candida and non-Aspergillus species; Polyene resistance; Resistance to allylamines; General conclusion; 3: Echinocandins: Resistance Mechanisms; Introduction; Structures; Echinocandin target: Fks1; Fks gene family; Fks1 structure-function Cell-free β-1,3-glucan synthase systemsEchinocandin uptake and efflux; Acquired echinocandin resistance: Fks hot spots 1 and 2; Differential echinocandin resistance: discovery of hot spot 3; Impact of Fks heterozygosity and redundancy on acquired resistance; Fks-independent acquired echinocandin resistance; Intrinsic echinocandin resistance: hot spot 1 substitutions; Intrinsic echinocandin resistance: hot spot 3 substitutions; Intrinsic resistance: mechanism to be determined; Stage-specific intrinsic resistance; Conclusions and future prospects; 4: Biofilms and Antifungal Resistance Introduction to fungal biofilmsFungal biofilm infections of humans; Current standard of care for fungal biofilm infections; Mechanisms of fungal biofilm drug resistance; Challenges and strategies to developing therapeutics for fungal biofilm infections; 5: Drug Combinations as a Strategy to Potentiate Existing Antifungal Agents; Introduction; In vitro and in vivo combinations with known antifungal agents; In vitro and in vivo combinations of non-antifungals with known antifungal agents; Systematic drug combination screenings Chemogenetic approaches in the exploration of drug interaction mechanismsConclusions; 6: Approaches to Detect Alternative Mechanisms of Resistance to Systemic Antifungals; Introduction; 'Omics' approaches; Mutants collections screening; Comparison with others species; Concluding remarks; 7: New Antifungal Discovery from Existing Chemical Compound Collections; Introduction; A new career for acetylsalicylic acid as an antifungal; Other non-traditional antimicrobial agents; Conclusion and future perspectives; 8: Exploring New Insights into Fungal Biology as Novel Antifungal Drug Targets Introduction |
| Record Nr. | UNINA-9910460916903321 |
| Norfolk, England : , : Caister Academic Press, , [2015] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antifungals : from genomics to resistance and the development of novel agents / / edited by Alix T. Coste, Institute of Microbiology, University Hospital Lausanne, and University Hospital Center, Lausanne, Switzerland, and Patrick Vandeputte, Host-Pathogen Interactions Study Group, UPRES-EA 3142, L'UNAM Angers University, and Parasitology-Mycology Laboratory, University Hospital Center, Angers, France
| Antifungals : from genomics to resistance and the development of novel agents / / edited by Alix T. Coste, Institute of Microbiology, University Hospital Lausanne, and University Hospital Center, Lausanne, Switzerland, and Patrick Vandeputte, Host-Pathogen Interactions Study Group, UPRES-EA 3142, L'UNAM Angers University, and Parasitology-Mycology Laboratory, University Hospital Center, Angers, France |
| Pubbl/distr/stampa | Norfolk, England : , : Caister Academic Press, , [2015] |
| Descrizione fisica | 1 online resource (346 p.) |
| Disciplina | 616.969061 |
| Soggetto topico |
Immunotherapy
Antifungal agents Biofilms |
| ISBN | 1-910190-02-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Contents; Contributors; Preface; 1: Molecular Mechanisms of Resistance of Candida spp. to Membrane-targeting Antifungals; Introduction; Azoles; Non-azole ergosterol biosynthesis inhibitors; Polyenes; Concluding remarks; 2: Point Mutations and Membrane-targeting Antifungal Resistance in Aspergillus fumigatus and Other Non-Candida Species; Introduction; Aspergillus fumigatus azole resistance in clinical settings; The molecular target of azoles, allylamines and polyenes: ergosterol and ergosterol biosynthesis pathway; Differences in ergosterol pathway between Aspergillus spp. and yeasts
Fungal 14-a sterol demethylases (SDMs): the main target for azole antifungalsA. fumigatus azole susceptibility patterns and mechanisms of azole resistance linked with CYP51 point mutations; Azole resistance in non-fumigatus Aspergillus; Azole secondary resistance linked with point mutations in the 14-α sterol demethylase enzyme in non-Candida and non-Aspergillus species; Polyene resistance; Resistance to allylamines; General conclusion; 3: Echinocandins: Resistance Mechanisms; Introduction; Structures; Echinocandin target: Fks1; Fks gene family; Fks1 structure-function Cell-free β-1,3-glucan synthase systemsEchinocandin uptake and efflux; Acquired echinocandin resistance: Fks hot spots 1 and 2; Differential echinocandin resistance: discovery of hot spot 3; Impact of Fks heterozygosity and redundancy on acquired resistance; Fks-independent acquired echinocandin resistance; Intrinsic echinocandin resistance: hot spot 1 substitutions; Intrinsic echinocandin resistance: hot spot 3 substitutions; Intrinsic resistance: mechanism to be determined; Stage-specific intrinsic resistance; Conclusions and future prospects; 4: Biofilms and Antifungal Resistance Introduction to fungal biofilmsFungal biofilm infections of humans; Current standard of care for fungal biofilm infections; Mechanisms of fungal biofilm drug resistance; Challenges and strategies to developing therapeutics for fungal biofilm infections; 5: Drug Combinations as a Strategy to Potentiate Existing Antifungal Agents; Introduction; In vitro and in vivo combinations with known antifungal agents; In vitro and in vivo combinations of non-antifungals with known antifungal agents; Systematic drug combination screenings Chemogenetic approaches in the exploration of drug interaction mechanismsConclusions; 6: Approaches to Detect Alternative Mechanisms of Resistance to Systemic Antifungals; Introduction; 'Omics' approaches; Mutants collections screening; Comparison with others species; Concluding remarks; 7: New Antifungal Discovery from Existing Chemical Compound Collections; Introduction; A new career for acetylsalicylic acid as an antifungal; Other non-traditional antimicrobial agents; Conclusion and future perspectives; 8: Exploring New Insights into Fungal Biology as Novel Antifungal Drug Targets Introduction |
| Record Nr. | UNINA-9910787429403321 |
| Norfolk, England : , : Caister Academic Press, , [2015] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antifungals : from genomics to resistance and the development of novel agents / / edited by Alix T. Coste, Institute of Microbiology, University Hospital Lausanne, and University Hospital Center, Lausanne, Switzerland, and Patrick Vandeputte, Host-Pathogen Interactions Study Group, UPRES-EA 3142, L'UNAM Angers University, and Parasitology-Mycology Laboratory, University Hospital Center, Angers, France
| Antifungals : from genomics to resistance and the development of novel agents / / edited by Alix T. Coste, Institute of Microbiology, University Hospital Lausanne, and University Hospital Center, Lausanne, Switzerland, and Patrick Vandeputte, Host-Pathogen Interactions Study Group, UPRES-EA 3142, L'UNAM Angers University, and Parasitology-Mycology Laboratory, University Hospital Center, Angers, France |
| Pubbl/distr/stampa | Norfolk, England : , : Caister Academic Press, , [2015] |
| Descrizione fisica | 1 online resource (346 p.) |
| Disciplina | 616.969061 |
| Soggetto topico |
Immunotherapy
Antifungal agents Biofilms |
| ISBN | 1-910190-02-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Contents; Contributors; Preface; 1: Molecular Mechanisms of Resistance of Candida spp. to Membrane-targeting Antifungals; Introduction; Azoles; Non-azole ergosterol biosynthesis inhibitors; Polyenes; Concluding remarks; 2: Point Mutations and Membrane-targeting Antifungal Resistance in Aspergillus fumigatus and Other Non-Candida Species; Introduction; Aspergillus fumigatus azole resistance in clinical settings; The molecular target of azoles, allylamines and polyenes: ergosterol and ergosterol biosynthesis pathway; Differences in ergosterol pathway between Aspergillus spp. and yeasts
Fungal 14-a sterol demethylases (SDMs): the main target for azole antifungalsA. fumigatus azole susceptibility patterns and mechanisms of azole resistance linked with CYP51 point mutations; Azole resistance in non-fumigatus Aspergillus; Azole secondary resistance linked with point mutations in the 14-α sterol demethylase enzyme in non-Candida and non-Aspergillus species; Polyene resistance; Resistance to allylamines; General conclusion; 3: Echinocandins: Resistance Mechanisms; Introduction; Structures; Echinocandin target: Fks1; Fks gene family; Fks1 structure-function Cell-free β-1,3-glucan synthase systemsEchinocandin uptake and efflux; Acquired echinocandin resistance: Fks hot spots 1 and 2; Differential echinocandin resistance: discovery of hot spot 3; Impact of Fks heterozygosity and redundancy on acquired resistance; Fks-independent acquired echinocandin resistance; Intrinsic echinocandin resistance: hot spot 1 substitutions; Intrinsic echinocandin resistance: hot spot 3 substitutions; Intrinsic resistance: mechanism to be determined; Stage-specific intrinsic resistance; Conclusions and future prospects; 4: Biofilms and Antifungal Resistance Introduction to fungal biofilmsFungal biofilm infections of humans; Current standard of care for fungal biofilm infections; Mechanisms of fungal biofilm drug resistance; Challenges and strategies to developing therapeutics for fungal biofilm infections; 5: Drug Combinations as a Strategy to Potentiate Existing Antifungal Agents; Introduction; In vitro and in vivo combinations with known antifungal agents; In vitro and in vivo combinations of non-antifungals with known antifungal agents; Systematic drug combination screenings Chemogenetic approaches in the exploration of drug interaction mechanismsConclusions; 6: Approaches to Detect Alternative Mechanisms of Resistance to Systemic Antifungals; Introduction; 'Omics' approaches; Mutants collections screening; Comparison with others species; Concluding remarks; 7: New Antifungal Discovery from Existing Chemical Compound Collections; Introduction; A new career for acetylsalicylic acid as an antifungal; Other non-traditional antimicrobial agents; Conclusion and future perspectives; 8: Exploring New Insights into Fungal Biology as Novel Antifungal Drug Targets Introduction |
| Record Nr. | UNINA-9910821292903321 |
| Norfolk, England : , : Caister Academic Press, , [2015] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
B Cell Activation in Biology and in Disease / / edited by Wanli Liu, Yingyue Zeng
| B Cell Activation in Biology and in Disease / / edited by Wanli Liu, Yingyue Zeng |
| Autore | Liu Wanli |
| Edizione | [1st ed. 2025.] |
| Pubbl/distr/stampa | Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2025 |
| Descrizione fisica | 1 online resource (126 pages) |
| Disciplina | 616.994 |
| Altri autori (Persone) | ZengYingyue |
| Soggetto topico |
Cancer - Treatment
Cancer Immunotherapy Immunology Tumors - Immunological aspects Cancer Therapy Cancer Biology Tumour Immunology |
| ISBN |
9789819610273
9819610273 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | -- Chapter 1_ Introduction. -- Chapter 2_ BCR Composition and Structure. -- Chapter 3_ Early Events in Antigen-Induced B Cell Activation. -- Chapter 4_ The Mechanism of IgG-BCR Mediated Memory Antibody Response. -- Chapter 5_ B Cell Mechanosensing. -- Chapter 6_ Techniques for Antigen-Induced B Cell Activation Imaging. -- Chapter 7_ Techniques to Measure B Cell Mechanosensing and BCR Conformational Changes. -- Chapter 8_ B Cell and Autoimmune Diseases. -- Chapter 9_ Tumor Immunity and Monoclonal Antibody Therapies. |
| Record Nr. | UNINA-9910983487403321 |
|
Liu Wanli
|
||
| Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2025 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Bacteriophages in health and disease / / edited by Paul Hyman and Stephen T. Abedon
| Bacteriophages in health and disease / / edited by Paul Hyman and Stephen T. Abedon |
| Pubbl/distr/stampa | Wallingford, Oxfordshire, U.K., : CABI, 2012 |
| Descrizione fisica | 1 online resource (296 p.) |
| Disciplina | 579.2/6 |
| Altri autori (Persone) |
HymanPaul (Paul Lawrence)
AbedonStephen T |
| Collana | Advances in molecular and cellular microbiology |
| Soggetto topico |
Bacteriophages
Immunotherapy |
| ISBN |
1-283-67086-0
1-84593-985-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Phages / Stephen T. Abedon -- Bacteriophages as part of the human microbiome / Andrey V. Letarov -- Diseases caused by phages / Sarah KuhlCA, Stephen T. Abedon, and Paul Hyman -- Prophage-induced changes in cellular cytochemistry and virulence / Gail E. Christie ... [et al.] -- The lion and the mouse : how bacteriophages create, liberate, and decimate pathogens / Heather Hendrickson -- Phages and bacterial epidemiology / Michele L. Williams and Jeffrey T. LeJeune -- Phages as therapeutic delivery vehicles / Jason Clark, Stephen T. Abedon, and Paul Hyman -- Clinical applications of phage display peptides / Don L. Siegel -- Phages and their hosts : a web of interactions applications to drug design / Jeroen Wagemans and Rob Lavigne -- Bacteriophage-based methods of bacterial detection and identification / Christopher R. Cox -- Phage detection as indication of fecal contamination / Lawrence D. Goodridge and Travis Steiner -- Phage translocation, safety, and immunomodulation / Natasza Olszowska-Zaremba ... [et al.] -- Phage therapy of wounds and related purulent infections / Catherine Loc-Carrillo, Sijia Wu, and James Peter Beck -- Phage therapy of non-wound infections / Ben Burrowes and David R. Harper -- Phage-based enzybiotics / Yang Shen ... [et al.] -- Role of phages in control of bacterial pathogens in food / Yan D. Niu ... [et al.] -- Phage therapy best practices / Stephen T. Abedon. |
| Record Nr. | UNINA-9910627292103321 |
| Wallingford, Oxfordshire, U.K., : CABI, 2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The Basics of Cancer Immunotherapy / / edited by Haidong Dong, Svetomir N. Markovic
| The Basics of Cancer Immunotherapy / / edited by Haidong Dong, Svetomir N. Markovic |
| Edizione | [2nd ed. 2024.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2024 |
| Descrizione fisica | 1 online resource (228 pages) |
| Disciplina | 616.994061 |
| Soggetto topico |
Immunotherapy
Medical sciences Immunology Cancer - Treatment Patient education Health Sciences Cancer Therapy Patient Education |
| ISBN |
9783031594755
9783031594748 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | The basic concepts in cancer immunology and immunotherapy -- Immune checkpoint inhibitors in oncology -- Bi-specific, T cell engaging antibodies including Tebentifusp -- Cell therapy for cancer: CAR-T, TIL -- Viral immunotherapy strategies in clinical practice: TVEC -- Chemotherapy for resistant cancer to ICI -- Radio-immunotherapy for refractory cancers -- Immunotherapy for melanoma and skin cancer -- Immunotherapy for lung cancer -- Immunotherapy for breast cancer -- Immunotherapy for genitourinary malignancies -- Immunotherapy for gastrointestinal malignancies -- Immunotherapy in the solid organ transplant recipient -- Management of immune-related adverse events from immune checkpoint inhibitor therapy -- Resources for patients undergoing immune therapy for cancer -- Immunotherapy for head and neck cancer. |
| Record Nr. | UNINA-9910872194703321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
A Beginner's Guide to Targeted Cancer Treatments and Cancer Immunotherapy
| A Beginner's Guide to Targeted Cancer Treatments and Cancer Immunotherapy |
| Autore | Vickers Elaine |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Newark : , : John Wiley & Sons, Incorporated, , 2024 |
| Descrizione fisica | 1 online resource (463 pages) |
| Disciplina | 616.994061 |
| Soggetto topico |
Immunotherapy
Drug targeting |
| ISBN |
9781119834090
1119834090 9781119834083 1119834082 9781119834076 1119834074 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover -- Title Page -- Copyright Page -- Contents -- Acknowledgments -- Praise For The First Edition -- About The author -- How To use This Book -- Chapter 1 An Introduction To cancer Cell Biology And genetics -- 1.1 Introduction -- 1.2 Dna Damage Is The cause Of every Cancer -- 1.2.1 Causes Of Dna Mutations -- 1.2.2 Types Of Dna Mutations -- 1.2.3 Numbers And Patterns Of dna Mutations In Cancer cells -- 1.2.4 Driver Mutations - Those That Affect Cancer Cell Behavior -- 1.2.5 The "usual Suspects" - Genes Commonly Mutated In many Cancers -- 1.3 The Defining Features (hallmarks) Of cancer Cells -- 1.3.1 Ten Hallmarks Of Cancer (plus Four Enabling Characteristics) -- 1.4 Variation Among Cancer Cells In a Single Tumor -- 1.4.1 Causes Of genetic Heterogeneity -- 1.4.2 Other Types Of heterogeneity -- 1.5 Cancer's Relationship With our Immune System -- 1.5.1 How Our Immune System Monitors For signs Of damage And destroys Faulty Cells -- 1.5.2 The Cancer-immunity Cycle -- 1.5.3 How Cancer Cells Avoid Destruction By The immune system -- 1.5.4 How Cancer Cells Ultimately Survive, And thrive, Among White Blood Cells -- 1.5.5 Elimination, Equilibrium, And escape -- 1.6 The Cancer Microenvironment -- 1.6.1 The Role Of white Blood cells -- 1.6.2 The Role Of other Cell Types -- 1.6.3 Angiogenesis -- 1.6.4 Two Examples Of the Importance Of the Tumor Microenvironment -- 1.7 Cancer Spread/metastasis -- 1.7.1 Routes Through Which Cancers Spread -- 1.7.2 Locations To which Cancers spread -- 1.7.3 Reasons Why Cancers Spread -- 1.8 Cancer Stem Cells -- 1.9 Unique Properties Of Hematological Cancers -- 1.9.1 Introducing Hematological Cancers -- 1.9.2 Most Of Them Develop From faulty B Cells -- 1.9.3 Certain Translocations Are Common To each Type And subtype -- 1.9.4 They Have Cd Antigens On their Surface -- 1.9.5 They Live In close Proximity To other White Blood Cells.
1.10 Obstacles That Prevent Us From curing Cancer -- 1.10.1 The Similarity Between Healthy Cells And cancer Cells -- 1.10.2 Differences Between Different Cancer Types -- 1.10.3 Cancer Spread -- 1.10.4 Intratumoral Heterogeneity -- 1.10.5 The Cancer Microenvironment -- 1.11 Final Thoughts -- References -- Chapter 2 Monoclonal Antibodies And small Molecules As cancer Treatments -- 2.1 Introduction -- 2.2 Antibody-based Cancer Treatments -- 2.2.1 Why Antibodies Make Good Cancer Treatments -- 2.2.2 How Antibody Therapies Have Changed Over The years -- 2.2.3 Mechanisms Of action Of antibody-based Cancer Treatments -- 2.2.4 Antibodies That Kill Cancer Cells Directly -- 2.2.5 Antibodies That Create A cancer-fighting Immune Response -- 2.2.6 Limitations Of antibody Treatments And reasons For side Effects -- 2.2.7 Uses Of monoclonal Antibody Treatments For cancer -- 2.2.8 Antibody Biosimilars -- 2.3 Small Molecule Cancer Treatments -- 2.3.1 Why Small Molecules Make Good Cancer Treatments -- 2.3.2 How Small Molecule Drugs Have Changed Over The years -- 2.3.3 Small Molecules That Block Kinases -- 2.3.4 Different Types Of kinase Inhibitors -- 2.3.5 Common Targets And uses Of kinase Inhibitors -- 2.3.6 Limitations Of kinase Inhibitors And reasons Why They Cause Side Effects -- 2.3.7 Small Molecules With Non-kinase Targets -- 2.4 Treatment Combinations -- 2.5 Final Thoughts -- References -- Chapter 3 Treatments That Target Cell Communication -- 3.1 Introduction -- 3.2 Growth Factor-controlled Signaling Pathways -- 3.2.1 Growth Factor Receptors: Some Basics -- 3.2.2 Growth Factor Receptors Activate Signaling Pathways -- 3.2.3 A Few Extra Things To know About Signaling Pathways -- 3.2.4 Signaling Pathways In cancer Cells -- 3.3 Growth Factor Receptors In cancer -- 3.3.1 Reasons For overactive Growth Factor Receptors On cancer Cells -- 3.4 Drugs That Target Egfr. 3.4.1 Monoclonal Antibodies That target Egfr -- 3.4.2 Kinase Inhibitors That Target Egfr -- 3.5 Drugs That Target Her2 -- 3.5.1 Monoclonal Antibodies That Target Her2 -- 3.5.2 Kinase Inhibitors That Target Her2 -- 3.6 Drugs That Block Other Growth Factor Receptors -- 3.6.1 Pdgfr And Kit Inhibitors -- 3.6.2 Fgfr Inhibitors -- 3.6.3 Met Inhibitors -- 3.6.4 Ret Inhibitors -- 3.6.5 Alk And Ros1 Inhibitors -- 3.6.6 Trka/b/c Inhibitors -- 3.6.7 Her3 Inhibitors -- 3.6.8 Flt3 Inhibitors -- 3.7 Targeting The mapk Signaling Pathway -- 3.7.1 Things To remember -- 3.7.2 Defects In The Mapk Signaling Pathway In Cancer Cells -- 3.7.3 Drugs That Block The Mapk Pathway -- 3.7.4 K-ras Inhibitors -- 3.7.5 B-raf Inhibitors -- 3.7.6 A Bit Extra On Mek Inhibitors -- 3.8 Targeting The pi3k/akt/mtor Signaling Pathway -- 3.8.1 Defects In The Pi3k/akt/mtor Pathway In Cancer Cells -- 3.8.2 Drugs That Block The Pi3k/akt/mtor Pathway -- 3.8.3 Pi3k Inhibitors -- 3.8.4 Dual Pi3k And Mtor Inhibitors -- 3.8.5 Akt Inhibitors -- 3.8.6 Mtor Inhibitors -- 3.9 Targeting The jak-stat Pathway -- 3.9.1 Defects In The Jak-stat Pathway In Cancer Cells -- 3.9.2 Jak2 Inhibitors -- 3.10 Bcr-abl Inhibitors -- 3.10.1 The Bcr-abl Protein -- 3.10.2 Imatinib: The First Bcr-abl Inhibitor -- 3.10.3 Second- And third-generation Bcr-abl Inhibitors -- 3.10.4 Allosteric Inhibitors Of bcr-abl -- 3.11 Final Thoughts -- References -- Chapter 4 More Targets And treatments -- 4.1 Angiogenesis Inhibitors -- 4.1.1 How Tumors Trigger Angiogenesis -- 4.1.2 Tumor Blood Vessels Are Weird -- 4.1.3 Why Block Vegf? -- 4.1.4 Why Angiogenesis Inhibitors Sometimes Work -- 4.1.5 Drugs That target Vegf Or Vegf Receptors -- 4.1.6 Everolimus And Temsirolimus -- 4.1.7 Kidney Cancer - A special Case -- 4.1.8 Hif-2alpha Inhibitor - Belzutifan -- 4.1.9 Why Angiogenesis Inhibitors Don't Always Work. 4.1.10 The Search For biomarkers -- 4.1.11 Combining Angiogenesis Inhibitors With Immunotherapy -- 4.2 Antibody Conjugates -- 4.2.1 The Structure Of Adcs -- 4.2.2 How Adcs Are Being Improved -- 4.2.3 An Example: Trastuzumab Deruxtecan -- 4.2.4 Common Targets Of Adcs And Treatment Examples -- 4.2.5 Who Are They Given To? -- 4.2.6 Reasons For Resistance To adcs -- 4.2.7 Side Effects Of Adcs -- 4.2.8 Other Types Of conjugate -- 4.3 Parp Inhibitors -- 4.3.1 What Is Parp? -- 4.3.2 How Do Parp Inhibitors Work? -- 4.3.3 What Are Brca Genes And Brca Proteins? -- 4.3.4 Why Are People With Inherited Brca Mutations So Likely To Develop Cancer? -- 4.3.5 Parp Inhibitors For People With Inherited Brca Gene Mutations And Breast Or Ovarian Cancer -- 4.3.6 Parp Inhibitors For Ovarian cancers In People Who Haven't Inherited A Brca gene Mutation -- 4.3.7 Parp Inhibitors As Treatments For Other Cancers -- 4.3.8 Biomarkers Of Response To Parp Inhibitors -- 4.3.9 Resistance Mechanisms To Parp Inhibitors -- 4.3.10 Overcoming Resistance To Parp Inhibitors -- 4.4 Cdk Inhibitors And other Cell Cycle-targeted Treatments -- 4.4.1 Cdks That Control The Cell cycle -- 4.4.2 Other Cdks -- 4.4.3 Why Cell Cycle Cdks Are Overactive In Cancer Cells -- 4.4.4 Cdk4/6 Inhibitors As Cancer treatments -- 4.4.5 Resistance To Cdk4/6 Inhibitors -- 4.4.6 Treatments That Target Other Cell Cycle Proteins -- 4.5 Hedgehog Pathway Inhibitors -- 4.5.1 Components Of the Hedgehog Pathway -- 4.5.2 Hedgehog Pathway Inhibitors -- 4.5.3 Smoothened Inhibitors As Treatments For basal Cell carcinoma And Medulloblastoma -- 4.5.4 Broadening The uses Of hedgehog Inhibitors -- 4.6 Targeting Epigenetic Enzymes -- 4.6.1 Epigenetic Control Of Our genes -- 4.6.2 Epigenetics And cancer -- 4.6.3 Treatments That Target Epigenetic Enzymes -- 4.7 Targeting Cell Survival -- 4.7.1 Bcl-2 Protects Cancer Cells From Apoptosis. 4.7.2 Mechanism Of Action Of Bcl-2 Inhibitors -- 4.7.3 How Else Can We trigger Apoptosis? -- 4.8 Targeting B Cell Receptor Signaling -- 4.8.1 The Normal Function Of Bcrs -- 4.8.2 How Bcr Signaling Goes Wrong In Cancer Cells -- 4.8.3 The Effects Of Blocking Bcr-controlled Signaling -- 4.8.4 Btk Inhibitors -- 4.8.5 Pi3k Inhibitors -- 4.8.6 Treatments That Target Cd79b Or Other Cell Surface Proteins -- 4.9 Nuclear Transport Inhibitors -- 4.9.1 Nuclear Transport And cancer -- 4.9.2 Exportin-1 inhibitors -- 4.10 Proteasome Inhibitors -- 4.10.1 About The proteasome -- 4.10.2 The Actions Of proteasome Inhibitors -- 4.10.3 Proteasome Inhibitors As Treatments For myeloma -- 4.10.4 Proteasome Inhibitors As treatments For other Cancers -- 4.11 Final Thoughts -- References -- Chapter 5 Immunotherapy With checkpoint Inhibitors -- 5.1 The Importance Of T Cells -- 5.1.1 The Importance Of T cells as a Target For immunotherapy -- 5.1.2 How Do The various T Cell-directed Immunotherapies Work? -- 5.2 An Introduction To Immune Checkpoint Inhibitors -- 5.2.1 The Normal Role Of checkpoint Proteins -- 5.2.2 Checkpoint Proteins Sometimes Suppress Cancer-fighting T Cells -- 5.3 How Checkpoint Inhibitors Work -- 5.3.1 Licensed Checkpoint Inhibitors -- 5.4 Lessons Learned From Checkpoint Inhibitor Trials -- 5.4.1 Some Patients With advanced Cancer Can effectively Be cured -- 5.4.2 Responders To checkpoint Inhibitor Monotherapy Are Usually In a Minority -- 5.4.3 The Earlier You can Give The Checkpoint Inhibitor The Better -- 5.4.4 There's Very Little Relationship Between Dose and response -- 5.4.5 Side Effects Are Unpredictable And can be life Long -- 5.4.6 There Are Various Possible Patterns Of response -- 5.4.7 Response Rates Are Highest In tumors With pd-l1/2 Gene Mutations -- 5.4.8 Early Data From Immunotherapy Trials Can be misleading. 5.5 Why Some Patients Benefit From Checkpoint Inhibitors And Others Don't. |
| Record Nr. | UNINA-9911019793003321 |
|
Vickers Elaine
|
||
| Newark : , : John Wiley & Sons, Incorporated, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
Immunotherapy
(136)
- Immunology (34)
- Cancer (28)
- Tumors - Immunological aspects (28)
- Cancer - Treatment (27)